135 results about "Cardiovascular disorder risk" patented technology

Disclosed are improvements in human nutrition involving a unique combination of natural products constituting anti-inflammatory compositions which can reduce cardiovascular disease risks as well as play a positive role in other conditions and diseases for which key indicators, especially selected from the group consisting of C-reactive protein (CRP) levels, cyclooxygenase-2 (COX-2), 5-lypoxygenase (5-LOX) expression and prostaglandin E2 (PGE-2) biosynthesis or any combination of these, are indicators. Therapeutic compositions preferably comprise curcumin, bilberry extract, grape seed extract, green tea extract and apple extract, in effective amounts individually and combined to provide a therapeutically significant reduction in one or more key indicators. Another exemplified therapeutic composition comprises: omega-3 rich refined fish oil, resveratrol, blueberry extract, grape seed extract, green tea extract and gamma and/or delta tocopherol, in effective amounts individually for the above benefits.

The invention provides compositions containing one or more sterol compounds and one or more fatty acid compounds. The invention also provides methods for reducing CVD risk factors such as LDL cholesterol levels.

This invention is based on the observed oxidative stress and increased risk on cardiovascular diseases in subjects with increased lipid peroxidation, in particular with women using oral contraceptives and in hormone replacement therapies. The invention provides compositions and combinations, particularly useful in preventing and or reducing the increased lipid peroxidation in subjects in need thereof. These compositions are based on the synergistic combination of zinc and/or a hydroxyl radical scavenger in reducing lipid peroxidation.

The invention relates to a cardiovascular healthcare management system which as an infomediary site with databases having information relating to cardiovascular disease risk factors such as age, blood pressure, LDL, HDL and subfractions thereof and cardiovascular disease management such as diet, exercise, drugs and cardiovascular educational materials. The physician can communicate electronically with the infomediary site to obtain patient test results and formulate a patient treatment plan from the diet, exercise and drug data. The physician can electronically communicate treatment plans to the patient through a record in the infomediary site. The patient can electronically communicate compliance information to the physician through the patient record. The infomediary site may also provide a case manager to provide initial draft treatment plans to the physician, gather patient history data and/or patient treatment plan compliance data.

Provided herein are methods for determining the metabolism of one or more sugars and/or fatty acids, and applications thereof. Such applications include determining the rate of glycogen synthesis and glycolysis, which are believed to be early markers for predicting elevated risk of diabetes and cardiovascular disease. Other applications include methods for screening drugs that effect sugar and/or fatty acid metabolism. The methods are useful for at least partially characterizing drugs for desirable or undesirable (toxic) characteristics. Drugs that are at least partially characterized using the methods of the invention can then be further developed in pre-clinical testing and clinical trials. Such drugs may be found to be useful in treating obesity, diabetes, cardiovascular disease, and other disorders of metabolism.

The present invention refers to a use of an ex vivo method comprising the determination of PlGF and sFlt-1 in a sample for diagnosis, risk stratification and/or monitoring of a vascular disease with atherosclerotic etiology, in particular a coronary heart disease such a unstable angina pectoris or myocardial infarction, and/or for estimation of the probability of developing such a disease, as well as for identification of a patient supposed to benefit from a therapy by agents reducing the risk for a cardiovascular disease. In the method (i) a ratio of [PlGF=high:sFlt-1=low], and/or (ii) a PlGF concentration in the upper two tertiles of a reference collective, and an sFlt-1 concentration in the lower tertile of the reference collective, and/or (iii) a PlGF result above a PlGF reference value, and an sFlt-1 result below an sFlt-1-reference value indicate an elevated probability for an adverse event. The present invention also refers to the used method. The present invention further refers to a diagnostic kit and its use as well as to an assay element and its use.

The disclosure describes methods, systems, and devices for analysis of lipoproteins and for diagnosing and/or determining risk of cardiovascular disease. In some embodiments, lipoproteins are separated by electrophoretically using a micro-channel device, and the data are analyzed using an adaptive method such as a neural network.

The LSAMP gene can be used for cardiovascular disease risk assessment, in particular Left Main Disease. The genetic risk attributable to LSAMP adds to known cardiovascular disease risk factors. Assessment of risk attributable to LSAMP permits early initiation of preventive and therapeutic strategies. Given the pronounced clinical risk associated with Left Main Disease, such risk assessment should significantly reduce morbidity and mortality.

The invention provides methods of preparation of lipoproteins from a biological sample, including HDL, LDL, Lp (a), IDL, and VLDL, for diagnostic purposes utilizing differential charged particle mobility analysis methods. Further provided are methods for analyzing the size distribution of lipoproteins by differential charged particle mobility, which lipoproteins are prepared by methods of the invention. Further provided are methods for assessing lipid-related health risk, cardiovascular condition, risk of cardiovascular disease, and responsiveness to a therapeutic intervention, which methods utilize lipoprotein size distributions determined by methods of the invention.

IgG and IgM autoantibody levels against phosphorylcholine in subjects with hypertension (diastolic pressure>95 mmHg) were determined at baseline in order to determine the importance of antibodies for the development of atherosclerosis. The results show that increases in intima-media thickness (IMT) at a follow-up four years after baseline were significantly less prevalent in subjects having high IgM autoantibodies to phosphorylcholine. The presence or absence of IgM autoantibodies against phosphorylcholine is thus related to an increased or decreased risk of developing ischemic cardiovascular diseases. A method to determine IgM antibodies toward phosphorylcholine is proposed in this invention to identify subjects at risk of developing ischemic cardiovascular diseases. Animal experiments show that medium to high levels of IgM antibodies can be detected in plasma after active immunization with a keyhole limpet hemocyanin (KLH)-phosphorylcholine conjugate. A pharmaceutical composition comprising a phosphorylcholine conjugate (active immunization) or a monoclonal antibody with specificity to a phosphorylcholine conjugate (passive immunization) is proposed and the use of these compositions as active or passive immunogens in the treatment or prevention of atherosclerosis.

The invention provides a cardiovascular disease early warning system based on the deep fusion of multiple physiological signals, which relates to the technical field of wearable health medical monitoring. The system includes a wearing device, a multi-physiological signal acquisition device, a transmission device, an intelligent terminal device and a cloud server. The multi-physiological signal acquisition device and the transmission device are arranged on the wearing device. The multi-physiological signal collecting device collects the physiological signal of the detected person and transmitsthe collected physiological signal to the intelligent terminal equipment through the transmitting device. The multi-physiological signal collecting device collects the physiological signal of the detected person and transmits the collected physiological signal to the intelligent terminal equipment. The intelligent terminal device has built-in program for judging whether the detected person is at risk of cardiovascular disease and transmitting the processed physiological signals to the cloud server. The cloud server has a built-in program for classifying and diagnosing diseases of multiple physiological signals of the wearer and feeding back the diseases to the intelligent terminal. The cardiovascular disease early warning system based on the deep fusion of multiple physiological signals provided by the invention provides more accurate reference for the evaluation of cardiac function and the diagnosis of cardiac disease.

Methods of lowering the plasma LDL-C levels in a patient on a stable dose of statin where the patient has an LDL-C level above treatment goal. Methods of decreasing a patient's risk for developing coronary heart disease or having a recurrent cardiovascular event wherein the patient is on a stable dose of statin and the patient has an LDL-C level above treatment goal.

The invention provides a feed addictive for producing a multiple nutrient enriched functional egg rich in zinc, selenium, and omega-3 poly-unsaturated fatty acid,. The feed addictive comprises the following main components: 48-55 parts of linseed, 3.2-3.6 parts of organic selenium, 8.7-9.0 parts of zinc methionine and 35-39 parts of bean meal, wherein the organic selenium is a substance mainly comprising organic selenium chelate with the selenium content of 1,500-20,000ppm. After the feed is fed to the layer chicken, the contents of zinc, selenium and omega-3 poly-unsaturated fatty acid and other multiple nutrients are increased; in addition, the feed addictive is a natural organic chelate and highly utilized by human body. If people eat the functional eggs enriching zinc, selenium and omega-3 poly-unsaturated fatty acid and other multiple nutrients, three kinds of nutrients can be effectively supplemented by only eating one egg a day and simultaneously people do not worry the risk of cardiovascular diseases caused by the superscalar of acceptable daily intake of cholesterolcholesterol.

The invention discloses a large data cardiovascular disease risk monitoring system. According to the system, personal information (including age, sex, blood pressure, height, weight, obesity index and the like) of health examinations, physical examinations and hospital treatment, and test data of blood routine, blood biochemistry and myocardial enzymes are used for monitoring the cardiovascular disease risk. The invention belongs to the application of large data in the field of health care, and further belongs to the crossing technical field of large data and health care. The invention aims at providing a simple, easy, practical and accurate cardiovascular risk monitoring system. The current monitoring of the cardiovascular disease risk is achieved mostly by enquiring a small sample amount of data collected by a questionnaire method such as disease history, family history and major risk factors for the cardiovascular disease and through the data of blood sugar collected by an instrument, total cholesterol and the like. The monitoring is controlled and managed by medical institutions and doctors so that users can not carry out the monitoring of the cardiovascular disease risk by themselves. Due to the fact that epidemiological features of a cardiovascular disease spectrum and risk factors in Chinese population are significantly different from the epidemiological features in western developed countries. The existing risk assessment tools in Europe and America are not suitable for the Chinese population. With the help of a large data value extraction technology, the large data cardiovascular disease risk monitoring system can monitor the cardiovascular disease risk for users and doctors and provide hope for human to monitor the cardiovascular disease risk by themselves and conquer the cardiovascular disease.

Single Nucleotide Polymorphisms sensitively predicting Advserse Drug Reactions (ADR) and Drug Efficacy Abs tract. The invention provides diagnostic methods and kits including oligo and/or polynucleotides or derivatives, including as well antibodies determining whether a human subject is at risk of getting adverse drug reaction after statin therapy or whether the human subject is a high or low responder or a good a or bad metabolizer of statins. The invention provides further diagnostic methods and kits including antibodies determining whether a human subject is at risk for a cardiovascular disease. Still further the invention provides polymorphic sequences and other genes. The present invention further relates to isolated polynucleotides encoding a phenotype associated (PA) gene polypeptide useful in methods to identify therapeutic agents and useful for preparation of a medicament to treat cardiovascular disease or influence drug response, the polynucleotide is selected from the group comprising: SEQ ID 1-168 with allelic variation as indicated in the sequences section contained in a functional surrounding like full length cDNA for PA gene polypeptide and with or without the PA gene promoter sequence.

The present invention provides methods for treating diseases and disorders that are associated with elevated levels of lipids and lipoproteins. The methods of the present invention comprise administering to a high cardiovascular risk patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P or alirocumab. The methods of the present invention are useful for treating high cardiovascular risk patients with hypercholesterolemia and elevated levels of other atherogenic lipoproteins that are not adequately controlled by maximum tolerated dose statin therapy. In particular, the methods of the present invention are useful for reducing cardiovascular risk and lowering atherogenic lipoproteins in high cardiovascular risk patients within 12 months following an acute coronary syndrome event despite a maximum tolerated dose statin therapy.

A system and method for diagnosing and managing patients at risk for cardiovascular disease. The system and method provides for automating the ordering of a number of advanced tests, compiling and evaluating test results, and producing an automated report which includes recommended disease management options.

The invention provides methods of preparation of lipoproteins from a biological sample, including HDL, LDL, Lp(a), IDL, and VLDL, for diagnostic purposes utilizing differential charged particle mobility analysis methods. Further provided are methods for analyzing the size distribution of lipoproteins by differential charged particle mobility, which lipoproteins are prepared by methods of the invention. Further provided are methods for assessing lipid-related health risk, cardiovascular condition, risk of cardiovascular disease, and responsiveness to a therapeutic intervention, which methods utilize lipoprotein size distributions determined by methods of the invention.

The invention discloses a cardiovascular disease risk prediction network model based on multiple parameters and a construction method thereof, relates to a risk prediction model, and solves the problems that an existing cardiovascular disease risk prediction model cannot predict multiple physiological parameters and is not ideal in prediction effect. The method comprises the following steps: establishing a cardiovascular disease data set; preprocessing the data set data, and dividing the data set into a training set and a test set according to the ratio of the number of the training set data to the number of the test set data being 7: 3; performing model construction: both the training set and the test set comprise samples and labels, model training is conducted on training set data through the minimum error of forward propagation and reverse propagation in the training process, and the trained model is evaluated through the test set data. The risk of suffering from cardiovascular diseases is evaluated by detecting multiple physiological parameters such as age, gender, chest pain type, resting blood pressure, serum cholesterol, fasting blood glucose, resting electrocardiogram, maximum heart rate and the like of a person.

The present invention provides methods, systems, devices, and software for determining values for one or more markers in order to characterize a subject's risk of developing cardiovascular disease or experiencing a complication thereof (e.g., within the ensuing one to three years). In certain embodiments, the markers are those derived from a blood sample using a hematology analyzer operably linked to a software application that is configured to compute a risk score for a subject based on the values for the markers detected in the blood sample.

This invention relates to methods of reducing risk of developing cardiovascular complications in diabetic patients. Specifically, the invention relates to the use of haptoglobin genotyping for determining the importance of maintaining tight glycemic control in diabetic subjects expressing Hp 2-2 allele.

The present invention relates to methods and devices for testing the physical condition of an individual. The methods and devices rely on the use of a marker of physical condition, and have applications including determining an individuals state of physical recovery from prior physical or athletic activity, determining an individuals physiological readiness for optimal physical performance, determining changes in the risk of (or for assessing progression of) cardiovascular disease in an individual, and for determining exercise and/or athletic training instructions for an individual based on their recovery state, physiological readiness to perform, and/or their cardiovascular disease risk status. The methods and devices require a comparison between the rate of increase in heart rate of an individual during a sub-maximal physical activity, and a predetermined reference measurement. A rate of increase in heart rate which is faster or slower than the predetermined reference measurement will allow determination of the individuals recovery state, physiological readiness to perform, and/or their cardiovascular disease risk status.

The invention relates to a method for assessing the risk of a cardiovascular disease and/or for diagnosing dyslipidemia in a patient, said method comprising: a) isolating in a blood sample obtained from said patient the high density lipoprotein (HDL) fraction or a subfraction thereof; and b) measuring in said HDL fraction or subfraction thereof the concentration of one or more biomarkers selected from the group consisting of Sphingosine-1-Phosphate (S1P), sphingomyelin (SM) and Apolipoprotein A-I (apoA-1).